Aisling Capital Management
Aisling Capital Management reported 14 stocks worth $472M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are BBIO (72.5%), GLUE (8.0%) and SNDX (6.1%). Compared with Q1 2026, the fund opened new positions in VTVT and trimmed BBIO.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  BBIO Bridgebio Pharma Inc | $342M | 72.5% | 4.6M | −500K (−10%) | 8 of 8 | |
| 2 |  GLUE Monte Rosa Therapeutics Inc | $37.6M | 8.0% | 1.6M | No change | 8 of 8 | |
| 3 |  SNDX Syndax Pharmaceuticals Inc | $28.8M | 6.1% | 1.3M | No change | 8 of 8 | |
| 4 |  CMPS Compass Pathways PLC | $20.3M | 4.3% | 1.4M | No change | 8 of 8 | |
| 5 |  BCAX Bicara Therapeutics Inc | $16.9M | 3.6% | 569K | No change | 8 of 8 | |
| 6 |  BBOT Bridgebio Oncology Therapeut | $7.8M | 1.6% | 1M | No change | 4 of 8 | |
| 7 |  SRRK Scholar Rock Hldg Corp | $4.2M | 0.9% | 77K | No change | 4 of 8 | |
| 8 |  URGN Urogen Pharma Ltd | $4M | 0.8% | 108K | No change | 3 of 8 | |
| 9 |  BMEA Biomea Fusion Inc | $3M | 0.6% | 2M | No change | 8 of 8 | |
| 10 |  ACRS Aclaris Therapeutics Inc | $2.3M | 0.5% | 434K | No change | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 13, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Aisling Capital Management 13F FAQ
What does Aisling Capital Management own?
Aisling Capital Management reported 14 stocks worth $472M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are BBIO (72.5%), GLUE (8.0%) and SNDX (6.1%). The table above lists every position in the filing (the top 10 without an account).
What did Aisling Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 1 new positions, 0 added to, 1 trimmed and 0 sold out. New positions include VTVT.
When will Aisling Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Aisling Capital Management's portfolio worth?
The Q2 2026 filing reports $472M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.